AZD9291 US Expanded Access Program

Summary

To provide access to AZD9291 for adult patients with advanced/metastatic, epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications

No indication recorded.